Why the study?
Does canagliflozin improve quality of life and satisfaction with physical and emotional health in patients with type 2 diabetes mellitus compared with sitagliptin?
Does canagliflozin improve quality of life and satisfaction with physical and emotional health in patients with type 2 diabetes mellitus compared with sitagliptin?
Answers are grounded in this paper and cite their sources.
Canagliflozin improves patient-reported quality of life and satisfaction with physical and emotional health compared to sitagliptin over 52 weeks in patients with type 2 diabetes mellitus.
The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.
No takes yet. Share an insight, caveat, or question.
Петунина et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: